KR20000061656A - Chinese medicine for cancer treatment - Google Patents

Chinese medicine for cancer treatment Download PDF

Info

Publication number
KR20000061656A
KR20000061656A KR1019990010867A KR19990010867A KR20000061656A KR 20000061656 A KR20000061656 A KR 20000061656A KR 1019990010867 A KR1019990010867 A KR 1019990010867A KR 19990010867 A KR19990010867 A KR 19990010867A KR 20000061656 A KR20000061656 A KR 20000061656A
Authority
KR
South Korea
Prior art keywords
cancer
tang
preparation
extract
cells
Prior art date
Application number
KR1019990010867A
Other languages
Korean (ko)
Other versions
KR100316379B1 (en
Inventor
성현제
정세영
윤유식
전원경
김연옥
Original Assignee
신민규
한국 한의학 연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신민규, 한국 한의학 연구원 filed Critical 신민규
Priority to KR1019990010867A priority Critical patent/KR100316379B1/en
Publication of KR20000061656A publication Critical patent/KR20000061656A/en
Application granted granted Critical
Publication of KR100316379B1 publication Critical patent/KR100316379B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/888Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888Pinellia
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: A Chinese medicinal composition for treating cancer is provided, which increases existing rate; decreases size of cancer; inhibits metastasis of cancer; which removes cancer cells by activating the immune system of living body not by attacking cancer cells directly. CONSTITUTION: A process for the preparation of Chinese medicinal composition for treating cancer comprises of: preparing herb medicines, and cutting finely; extracting the dried herb medicines using hot water; leaving the herb medicines in distilled water 1000ml at room temperature, boiling for 30minutes, and separating the extract and residue using filter sheath; adding distilled water 1000ml to the residue, boiling again for 30minutes, and filtering again; centrifuging the two extracts for 15minutes at 8000*g to get the supernatant; concentrating the extract under decompression, and freeze-drying to get the brown extract 13.4g. The composition contains 6-24wt.% of the AnJoongSan preparation, 25-100wt.% of the Bowhawhan preparation, 1-6wt.% of Sepia esculenta, Gallus domesticus, Scolopendra subspinipes, Rhus verniciflua, Scutellaria bardata, Anemarrhena asphodeloides each, and 0.25-1wt.% of Aucklandia lappa.

Description

암치료용 한방 조성물 {Chinese medicine for cancer treatment}Chinese medicine composition for cancer treatment {Chinese medicine for cancer treatment}

본 발명은 암치료용 한방 조성물에 관한 것으로, 안중산(安中散)제제와 보화환(保和丸)제제를 혼합하고 해표소 등의 한방을 부가한 것을 특징으로 하는 암치료용 한방 조성물에 관한 것이다. 본 발명의 한방 조성물은 아가리쿠스 버섯 추출물과 혼합하는 경우 더욱 현저한 상승효과를 나타낸다.The present invention relates to a herbal composition for cancer treatment, comprising a combination of Anjungsan and Bohwahwan formulations, and adding herbal such as a checkpoint to a herbal composition for cancer treatment. It is about. The herbal composition of the present invention shows a more significant synergistic effect when mixed with Agaricus mushroom extract.

암은 1990년대 후반인 현재 사망원인 1위를 차지하고 있으며 증가추세에 있다. 국내 50대, 60대 사망자의 30%가 암으로 죽어가고 있으며 암 중에서는 위암,간암, 폐암 순으로 사망빈도가 높다. 서양의학으로는 초기에 발견된 암일 경우 수술이나 방사선, 화학요법으로 치료가 가능하나 말기 암이나 전이된 암의 경우는 시한부 인생을 살아가야 하는 상황이며 방사선 요법, 화학요법의 부작용 또한 큰 문제로 대두되고 있다. 많은 암 환자들이 방사능, 화학요법의 부작용으로 고생하다가 생명을 잃고 있는 현실이다. 한방은 서양의학으로 고치지 못하는 많은 경우에적용되어질 수 있으며 서양 의학적 요법에 비해 부작용이 적다고 할 수 있어 암 환자의 삶의 질을 향상시킬 수 있다.Cancer is the number one cause of death in the late 1990s and is on the rise. 30% of the 50s and 60s deaths in Korea are dying of cancer, and among the cancers, the most frequent deaths are gastric cancer, liver cancer and lung cancer. In Western medicine, early cancers can be treated with surgery, radiation, or chemotherapy, but late stage cancers or metastatic cancers require a life-long life, and side effects of radiation therapy and chemotherapy are also a major problem. It is becoming. Many cancer patients are suffering from side effects of radiation and chemotherapy, and are losing their lives. Herbal medicine can be applied to many cases that can not be repaired by Western medicine and can be said to have fewer side effects than Western medical therapy can improve the quality of life of cancer patients.

국내에서도 부작용이 적은 천연물에서 항암제를 개발하려는 시도가 이루어지고 있어 많은 특허가 출원 및 공개되었지만 대부분 식물(한국 특허 공개공보 제96-028914 호 등)이나 버섯 류(한국 특허 공개공보 제 97-021287 호 등)의 성분들을 이용한 항암제 개발에 대한 것이고 한의학적 원리에 입각하여 구성된 처방으로이루어진 경우는 극히 드문 상황이다.Attempts have been made to develop anticancer drugs in natural products with few side effects, but many patents have been filed and disclosed, but most plants (Korea Patent Publication No. 96-028914, etc.) and mushrooms (Korean Patent Publication No. 97-021287) It is about the development of anti-cancer drugs using the ingredients of Etc.), and it is very rare that the prescription is made based on the principle of oriental medicine.

몇몇 공개된 한방 항암제제의 경우에도 과학적인 효능의 검증이 부족하였다. (한국 특허 공개 공보 제 95-165 호, 한국 특허 공개 공보 제 94-13527 호, 한국 특허 공개 공보 제 97-73600 호).Some published herbal anticancer drugs also lacked a test of scientific efficacy. (Korean Patent Publication No. 95-165, Korean Patent Publication No. 94-13527, Korean Patent Publication No. 97-73600).

또, 아가리쿠스 버섯 (Agaricus Blazei Murill)은 열대 산간지역에 자생하던것을 근래 한국, 일본 등지에서 인공재배에 성공하면서 대량공급이 가능하게 되었으며 베타글루칸, 불포화지방산, 식이섬유, 비타민 B, D 등과 같은 인체에 유익한성분을 다량함유하고 있고, 항암효과가 널리 알려져 있다. 아가리쿠스 버섯에 대한 국내 특허로는 아가리쿠스 버섯 추출물을 감미제, 구연산 포도당 등의 음료용 보조제와 함께 첨가하여 제조된 건강음료에 관한 건이 공개되어 있다( 한국 공개공보 제 98-75714 호).In addition, Agaricus Blazei Murill has grown naturally in tropical mountains and has been successfully grown in Korea and Japan, and has been able to supply large quantities.Agaricus Blazei Murill can be supplied in large quantities. It contains a large amount of beneficial ingredients, and its anticancer effect is widely known. As a domestic patent for Agaricus mushroom, a case related to a health beverage manufactured by adding Agaricus mushroom extract together with a beverage adjuvant such as sweetener and citric acid glucose is disclosed (Korean Publication No. 98-75714).

따라서, 본 발명의 목적은 한의학적 원리 및 임상 증후에 입각하여 생체 면역계를 활성화시켜 암을 제거함으로써 부작용 없고 암 환자의 삶의 질을 향상시킬수 있는 암 치료용 한방 조성물을 제공하고자 하는데 있다.Accordingly, an object of the present invention is to provide a herbal composition for treating cancer that can improve the quality of life of cancer patients without side effects by activating the biological immune system based on the principles of Chinese medicine and clinical symptoms to remove cancer.

도 1은 B16 흑색종 암세포의 폐 전이에 있어서 대조군과 본 발명의 한방 조성물 투여군 생쥐의 폐를 비교한 것이다.Figure 1 compares the lungs of the control group mice with the herbal composition-administered group of the present invention in lung metastasis of B16 melanoma cancer cells.

상기의 본 발명의 목적은 6-24중량부의 안중산(安中散) 제제; 25-100중량부의 보화환(保和丸)제제; 그리고 각각 1-6중량부의 해표소, 계내금, 오공, 건칠, 반지련, 지모 및 0.25-1중량부의 목향으로 이루어진 암치료용 한방 조성물에 의해 달성된다.An object of the present invention described above is 6-24 parts by weight of an intermediate acid formulation; 25-100 parts by weight of a boron ring preparation; And it is achieved by the herbal composition for cancer treatment which consists of 1-6 parts by weight of each of the mark, the inner gold, five holes, dried lacquer, ring lotus, hair, and 0.25-1 parts by weight of neck.

이하 이 한방 조성물을 가미보아탕(加味保我湯)으로 명명한다.Hereinafter, this herbal composition is called kamiboa-tang (加味 保 我 湯).

또, 본 발명의 한방 조성물에 아가리쿠스 버섯 추출물을 혼합하게 되면 암치료에 상승효과를 나타내게 되는데 이 아가리쿠스 버섯을 혼합한 조성물은 보가리탕으로 명명한다.In addition, when the agaricus mushroom extract is mixed with the herbal composition of the present invention, a synergistic effect is shown in cancer treatment. The composition of the agaricus mushroom is named Bogari-tang.

한의학의 문헌에 위암이라는 명칭이 나타나 있지는 않지만, 반위, 위완통, 심하비, 격증등의 병증이 위암의 증상과 유사한 것으로 볼 수 있으며, 위암의 병기는 기체울결, 음식부절, 비위허한, 기체혈어로 요약되는데 이로 인해 위부의 동통과 위의 하기가 안되어 생기는 위기상역, 음식물 적체가 있게 된다.Although the name of stomach cancer does not appear in the literature of Chinese medicine, the symptoms of stomach cancer, gastric pain, deep heart attack, and severe symptoms are similar to those of gastric cancer. In summary, this leads to pain in the stomach and crisis and food buildup caused by the stomach's discomfort.

가미보아탕(加味保我湯)은 위암에 대한 한의학적 병기와 임상증후에 입각하여 창방된 것으로 『태평혜민화제국방(太平惠民和劑局方)』에 수록되어있는 안중산(安中散)과 『고금의감(古今醫監)』의 보화환(保和丸)을 합한 처방에 위암의 병기를 고려한 다수의 단미제를 가하여 구성한 것이다.Kamiboa-tang was founded on the oriental medical stage and clinical symptoms of gastric cancer, and is listed in the Taepyeong Hyemin-gukbang National Defense Center (安 中 散). And Bohwahwan of 『Goldi Feeling (古 금)』, which consisted of a number of sweeteners considering the stage of gastric cancer.

안중산(安中散)의 적응증은 『태평혜민화제국방(太平惠民和劑局方)』 에 따르면 비동번위(脾疼飜胃), 토산수(吐酸水), 한기유체(寒氣留滯), 정적부소(停積不消), 흉격팽만(胸膈脹滿), 공자복협(攻刺腹脇), 악심구역(惡心嘔逆), 면황기수(面黃肌瘦)로서 비위(脾胃)의 기능감퇴로 인한 소화불량과 기기울체(氣機鬱滯)가 가져오는 통증 및 제반 위장 증상에 이용된다고 볼 수 있다. 그 구성 약재는 육계, 건강, 고량강, 현호색, 모려, 감초, 회향이다.The indication of Ahn Jung-san is based on the non-parallel, oxal water, and cold-air fluids, according to the Taepyeong Hyeminjeung National Defense. ), Static bloating, swelling of the thorax, celiac strait, wicked heart zone, cotton sulphate and dysfunction of the stomach It can be said that it is used for pain and general gastrointestinal symptoms caused by indigestion and instrumental depression. Its constituents are broiler, health, Goyanggang, Hyun-ho-ri-colored, rice, licorice, fennel

보화환(保和丸)은 『고금감의(古今醫監)』에 따르면 식적정제(食積停滯)로 흉완비만(胸脘??滿), 복장시통(腹脹時痛), 애부염식(??腐厭食), 대변부조(大便不調)가 그 적응증으로서, 음식으로 인한 위장 손상을 치료하고 음식적체(飮食積滯)가 계속될 시에 사용하면 소통(消通) 효과를 가져오는 처방이라고 할 수 있다. 그구성약재는 백출, 진피, 반하, 복령, 신곡, 산사, 연교, 향부자, 후박, 나복자, 황금, 지실, 맥아, 황련이다.Bohwa-hwan is a food tablet according to Kogumgam-eui (今 醫 監).腐 厭食) and stool relief (大 便 不 調) are indications that treat the gastrointestinal damage caused by food and when used in the absence of food (飮 食 積滯) is a prescription that brings a communication effect. Can be. Its medicinal herbs are Baekchul, Dermis, Banja, Fuling, Singok, Sansa, Fellowship, Hyangbuja, Hubak, Nabojak, Golden, Jisil, Malt, Husband.

따라서 가미보아탕(加味保我湯)의 기본 입방원리(入方原理)는 위암의 일반적증후를 개선하는 것과 위장의 기능을 회복하는 것에 주를 두는 것으로서 한의학적병기로 요약한다면 비위허(脾胃虛), 기체(氣滯)와 식적(食積), 담결습취(痰結濕聚)이고 치료원칙으로 요약한다면 보비위(補脾胃), 이기(理氣), 소식화적(消食化積),거담(祛痰), 거습(祛濕)이라고 할 수 있다.Therefore, the basic cubic principle of Kamiboa-tang (入 方 原理) focuses on improving the general symptoms of gastric cancer and restoring gastrointestinal function. , Gas, food, and phlegm, and summarized by the principle of treatment, Bowi, ego, news, and expectoration It can be called rough.

가미보아탕의 구체적인 방제구성은 안중산(安中散)과 보화환(保和丸)을 합하면서 적응증에 효과를 높이기 위해 이기지통(理氣止痛), 조중화위(調中和胃)하는 茴香과 제산지통(制酸止痛)작용이 강한 해표소을 사용하고 여기에 소식화적(消食化積)하는 계내금과 산결해독(散結解毒), 청열화담(淸熱化痰)하는 오공, 파적취(破積聚)하는 건칠을 가하고 그 밖의 청렬해독(淸熱解毒), 화어(化瘀), 소종(消腫)효능이 있는 반지련, 소담(消痰), 윤폐(潤肺) 효능이 있는 지모, 및 치적년현벽(治積年??癖)효능이 있는 목향을 가한 것이다.The specific control composition of kamiboa-tang is the combination of Ahnji-san and Bohwa-hwan, with the scents of Igiji-tong and Jojung-hwa in order to enhance the indication. It uses the strong antagonism of the antacid pain, and it uses the in-situ money, the detoxification, and the blue-green stalks, and the reddish odor. 건 (련 解), other detoxification, firefish, soybean smelting with small potency, sodam, lubricating thyme, and It is the effect of the neck with the effect of the cumulative year wall (治 積年 ?? 癖).

가미보아탕은 위암에 대한 한의학적 병기와 임상증후에 입각하여 창방된 것으로 항암효과의 확인을 위하여 암세포에 대한 세포독성 실험 및 마우스를 이용한암 생존율 연장 실험, 암 크기 감소 실험, 암 전이 억제 실험과 면역 증강 실험을수행하였다. 이하 본 발명을 실시예를 들어 구체적으로 설명한다. 그러나 본 발명이 이 실시예로만 한정되는 것은 아니다.Gamiboa-tang was established based on the oriental medical stage and clinical symptoms of gastric cancer. Cytotoxicity studies on cancer cells and cancer survival prolongation experiments, cancer size reduction experiments, cancer metastasis suppression experiments and immunity were performed to confirm anticancer effects. Augmentation experiments were performed. Hereinafter, the present invention will be described in detail with reference to Examples. However, the present invention is not limited only to this embodiment.

[실시예 1]Example 1

〈가미보아탕의 제조〉<Production of kamiboa bath>

가미보아탕의 구성은 표 1과 같다. 한방은 경동시장에서 구입하였고, 잡질을제거한 다음 세절하여 실험에 사용하였다. 잘 건조되어진 한방을 세절하여 열수를이용하여 추출하였다. 한방 72g에 증류수 1000 ㎖을 넣고 실온에 24시간 방치한다음 30분 동안 끓인 후 여과지를 이용하여 추출액과 약재를 분리하였다. 약재에 증류수를 1000 ㎖ 부은 후 30분간 재탕하고 다시 여과하여 추출액을 얻었다. 두 추출액을 합한 후 8,000×g에서 15분간 원심분리하여 상층액만 취하였다. 이 상층액을 회전증발기(Buchi RE 121, Switzerland)로 60℃ 수조에서 감압 농축한 후 동결건조기로 동결 건조하여 짙은 갈색의 추출물 13.4g을 얻었다. 이것을 인산염 완충용액 (phosphate buffered saline)에 적정농도로 녹여 암세포 및 실험동물에 투여하였다.The composition of Kamiboa-tang is shown in Table 1. Herbal medicine was purchased at Gyeongdong market, and after removing miscellaneous goods, it was cut and used for experiments. The well-dried herbs were chopped and extracted using hot water. 1000 ml of distilled water was added to herbal medicine, which was allowed to stand at room temperature for 24 hours, and then boiled for 30 minutes, and the extract and the medicinal herb were separated using filter paper. 1000 ml of distilled water was poured into the medicine, re-heated for 30 minutes, and filtered again to obtain an extract. The two extracts were combined and centrifuged at 8,000 × g for 15 minutes to extract only the supernatant. The supernatant was concentrated under reduced pressure in a 60 ° C. water bath using a rotary evaporator (Buchi RE 121, Switzerland) and lyophilized with a lyophilizer to obtain 13.4 g of a dark brown extract. This was dissolved in an appropriate concentration in phosphate buffered saline (administration) and administered to cancer cells and experimental animals.

[표 1]가미보아탕의 구성[Table 1] Composition of kamiboa-tang

[실시예 2]Example 2

〈암세포주에 대한 세포독성〉<Cytotoxicity to Cancer Cell Lines>

한국인 유래 위암 세포주인 SNU-1 (human gastric carcinoma)을 사용하여 MTT assay (Moseman, T., J. Immunol. Methods, 65: 5510, 1983) 방법을 이용하여측정하였다. 이 실험에서 최종적으로 얻어지는 실험군의 흡광도 값은 MTT가 생존하는 세포의 효소에 의해 환원된 양을 나타내는 것으로 각 웰(well)에 살아있는 세포수와 비례한다. 흡광도로 나타나지는 세포의 생존율을 50%로 감소시키는 시료의 농도(IC50)값을 항암효과의 지표로 사용하였다. 실험결과 가미보아탕은 IC50값이 200㎛/㎖ 이상으로 위암 세포주에 대하여 직접적인 세포독성은 없는 것으로 나타났다.Human gastric carcinoma (SNU-1), a Korean-derived gastric cancer cell line, was measured using an MTT assay (Moseman, T., J. Immunol. Methods, 65: 5510, 1983). The absorbance values of the experimental group finally obtained in this experiment represent the amount of MTT reduced by the enzyme of surviving cells, which is proportional to the number of living cells in each well. The concentration of the sample (IC 50 ), which reduces the survival rate of cells, expressed by absorbance, to 50%, was used as an index of anticancer effect. As a result, Gamiboa-tang showed no direct cytotoxicity against gastric cancer cell line with IC 50 value of 200µm / ml or more.

[실시예 3]Example 3

〈암 생존기간 연장 실험〉〈Cancer survival extension experiment〉

ICR 마우스를 대조군, 실험군으로 각각 10마리씩 나누고, Sarcoma-180 암세포를 한 마리 당 2×105개씩 복강 내에 주사한 뒤 24시간 후부터 한방을 1일 l회 연속으로 경구 투여하면서 수명을 관찰하고 생존증가율(increase of life span : ILS)을 구하였다. 대조군은 동일 부피의 인산염 완충 용액을 투여하였다.ICR mice were divided into 10 groups in the control and experimental groups. Sarcoma-180 cancer cells were injected intraperitoneally with 2 × 10 5 cells per mouse. (increase of life span: ILS) was obtained. The control group received the same volume of phosphate buffer solution.

T : 한방 투여군의 평균 생존기간T: Mean survival time of herbal group

C : 대조군의 평균 생존기간C: mean survival time of control group

본 실험에서는 대조군의 경우 17일부터 32일 경과시 까지 사망개체가 발견되었으며 평균수명이 21.0으로 나타났다. 이에 비하여 가미보아탕은 20일부터 사망하기 시작하여 40일까지 3마리가 살아남았으며 평균생존일 수 29.5를 나타내 ILS(%) 140으로 탁월한 항암효과를 나타내는 것을 확인할 수 있었다 (표 2).In this experiment, the control group was found to have died from 17 days to 32 days and the average life span was 21.0. In contrast, Gamiboa-tang started to die from 20 days and survived until 40 days, and the average survival time was 29.5, indicating an excellent anticancer effect with ILS (%) 140 (Table 2).

[표 2] 가미보아탕의 암생존기간 연장효과[Table 2] Effects of Gamiboa-tang on Cancer Survival

[실시예 4]Example 4

〈고형암 크기 억제 실험〉<Solid Cancer Size Suppression Experiment>

B16 melanoma 암세포를 배양하여 C57BL/6 마우스에 106세포/마리로 옆구리 피하에 주사하고 하루 후부터 1일 1회 200 mg/Kg의 가미보아탕을 15일간 경구 투여하였다. 대조군에는 동일한 부피의 인산염 완충 용액을 경구 투여하였다. 15일후 쥐를 치사시키고 부검하여 고형암을 분리한 후 전자 저울로 무게를 측정하였다. 실험결과 통계적으로 유의성있는 암 크기의 감소가 관찰되었다 (표 3).B16 melanoma cancer cells were cultured and injected into the C57BL / 6 mice subcutaneously at 10 6 cells / horse and 200 mg / Kg of gamiboa-tang was orally administered once a day for 15 days. The control group was orally administered an equal volume of phosphate buffer solution. After 15 days, rats were killed and necropsied to separate solid cancers and weighed with an electronic balance. Experimental results showed a statistically significant decrease in cancer size (Table 3).

[표 3] 가미보아탕의 고형암 크기 감소 효과[Table 3] Effect of Gamiboa-tang on Reduction of Solid Rock Size

a) : 평균 ± 표준편차a): mean ± standard deviation

* : 스튜던트 T테스트 결과 대조군에 비해 통계적으로 유의적인 감소를 보임*: Student's T test showed statistically significant decrease compared to control

( p〈0.05).(p <0.05).

[실시예 5]Example 5

〈암전이 억제 실험〉<Cancer metastasis suppression experiment>

실험에 사용된 동물은 대한실험동물센터에서 4주령의 C57BL/6계의 암컷 생쥐를 분양받아 4주일간 본 동물사육실에서 적응시킨 뒤 실험에 사용하였다. 5×105개의 B16 흑색종세포를 0.2㎖의 인산염 완충 용액에 현탁시켜 C57BL/6 마우스의 미정맥에 주입하고 24시간 이후부터 1일 1회 한방을 경구 투여하였다. 14일 후 마우스를 치사시켜 폐를 적출한 후 해부 현미경으로 폐의 표면에 생긴 흑색종 군락을 관찰하였다. 실험결과, 대조군과 가미보아탕 투여군 간에 도 1에서와 보는 바와같이 전이정도에 감소가 나타났다.The animals used for the experiment were 4 weeks old C57BL / 6 female mice at the Korea Experimental Animal Center, which were adapted for 4 weeks in the animal kennel and used for the experiment. 5 × 10 5 B16 melanoma cells were suspended in 0.2 ml of phosphate buffer solution and injected into the caudal vein of C57BL / 6 mice, followed by oral administration once daily after 24 hours. After 14 days, the mouse was lethal and the lungs were removed. Then, the melanoma colony formed on the surface of the lung was observed under a dissecting microscope. As a result, as shown in FIG.

[실시예 6]Example 6

〈면역증강 효과 실험〉〈Immune Boosting Effect Experiment〉

실험동물을 이용한 항암 실험에서 생존율 증가, 암크기 감소, 암전이 감소 등 항암 효과가 높게 관찰된 가미보아탕에 대하여 생체 면역계에 미치는 영향에 대한 연구가 이루어 겼다. 가미보아탕의 경우 암세포 세포 독성 실험의 결과 IC50이 200 ㎍/㎖이상으로 암세포에 대한 직접적인 효과가 없는 것으로 나타났으므로, 가미보아탕의 항암 효과는 암세포에 대한 직접적인 성장 억제 효과가 아니라 면역 기능을 증진 시켜 면역계로 하여금 암세포를 제거하게 하는 효과라고 생각되는바 이를 확인하는 실험을 수행하였다.In the anti-cancer experiments using experimental animals, a study was conducted on the effects of kamiboa-tang on the biological immune system with high anti-cancer effects such as increased survival rate, reduced cancer size, and reduced cancer metastasis. Gamiboa-tang showed no direct effect on cancer cells with IC 50 of 200 ㎍ / ml as a result of cancer cell cytotoxicity test. Therefore, the anti-cancer effect of gamiboa-tang is not a direct growth inhibitory effect on cancer cells but an immune function. The experiment was performed to confirm that the immune system is thought to be effective in removing cancer cells.

○적혈구 응집소가에 대한 효과○ Effect on hemagglutinin

항원으로는 면양적혈구(SRBC, KOREA MEDIA OORP.)를 사용하여 4℃에서 보존하며, 보존 1주일 이내의 것만 사용하였다. 가미보아탕 및 생리식염수를 1일 1회 21일간 경구투여한 후 대조군과 실험군의 미정맥에 5×108cell/㎖의 농도의 면양적혈구 부유액을 0.2㎖를 주사하여 면역시켰다. 마우스를 에테르로 가볍게 마취하여해부판에 고정하고 1회용 주사기(syrintube, 보인)로 심장에서 약 1㎖ 채혈한 다음 1시간동안 온실에서 방치하고 잘은 유리봉으로 응고된 혈액을 수회 휘저은 후 원심분리기로 2,000 rpm 에서 30분간 원심분리시켜 상층액인 혈청을 취하였다. 이 혈청을 56℃에서 30분간 비동화시킨 후 적혈구 응집소가의 측정에 사용하였다. Microtitration plate(Limbro chemical Co.,Conn., U.S.A)의 각 well에 인산완충염용액으로 2배 계열희석한 혈청 25㎕에 0.5% 면양적혈구 부유액 50㎕씩 가하여 잘 혼합한 다음 37℃ 5% C02배양기내에서 18시간 방치한 후 적혈구응집반응을 관찰 판독하였으며, 적혈구응집을 일으키는 혈청의 최대희석배수를 응집소가로 측정하였다. 가미보아탕 투여군과 대조군간의 면양적혈구에 대한 응집소가를 측정하여 log2값으로 계산하였던 바, 대조군이 5.98 ± 2.24, 가미보아탕 50 ㎎/kg 투여군이 6.72 ±3.14로 통계적으로 유의성 있는 차이를 보이지 않았다 (표 4).Antigens were stored at 4 ° C using cotton blood cells (SRBC, KOREA MEDIA OORP.), And only those within 1 week of storage were used. Gamiboa-tang and physiological saline were orally administered once a day for 21 days, and then immunized with 0.2 ml injection of cotton wool suspension of 5 × 10 8 cell / ml in the control vein and the experimental group. The mouse was lightly anesthetized with ether, fixed on an anatomical plate, collected about 1 ml from the heart with a disposable syringe (syrintube, shown), left in the greenhouse for 1 hour, and the coagulated blood was stirred several times with a glass rod. The separator was centrifuged at 2,000 rpm for 30 minutes to obtain the supernatant serum. This serum was inactivated at 56 ° C. for 30 minutes and then used for the measurement of hemagglutination titer. To each well of a microtitration plate (Limbro chemical Co., Conn., USA), add 50 µl of 0.5% sheep red blood cell suspension to 25 µl of 2-fold dilution serum with phosphate buffered saline solution, and mix well. 37 ° C 5% C0 2 After standing for 18 hours in the incubator, the hemagglutination reaction was observed and read, and the maximum dilution factor of the serum causing the hemagglutination was measured at agglutination titer. Agglutination value of sheep blood cells between gamiboa-tang and control group was measured and calculated as log 2 value. The control group showed 5.98 ± 2.24, and Gamiboa-tang 50 mg / kg group showed 6.72 ± 3.14. (Table 4).

[표 4] 가미보아탕이 적혈구 응집소가에 미치는 영향[Table 4] Effect of Gamiboa-tang on Hemagglutinin Value

a ) : 평균 ± 표준편차a): mean ± standard deviation

○ 로제트 (rosette) 형성 세포수의 측정○ Measurement of rosette forming cell number

채혈이 끝난 마우스를 경추탈골로 치사시킨 후 복부를 알콜로 완전히 도포하여 무균적으로 비장을 적출한 다음 비장 주위의 조직들을 조심스럽게 제거하고 나서 차가운 RPMI 배지로 세척하였다. 준비된 비장을 잘게 으깬 뒤 조직파편을 제거한 후 RPMI 배지로 2회 세척하였다. 그 후 멸균된 증류수로서 적혈구를 파괴한 후 10배의 행크염 용액 (Hank's balanced salt solution, HBSS)으로 2회 세척하고 다시 RPMI 배지로 1회 세척한 후, 10% 소태아혈청이 첨가된 RPMI 배지에 비장임파구를 재부유하였다. 비장세포 부유액을 1×107cells/㎖ 의 농도로 조정한 것과 3×108cells/㎖ 의 농도로 조정한 면양적혈구 부유액을 0.5㎖씩 혼합하여 원심분리로 980 rpm에서 5분간 원심분리시킨 후 4℃에서 30분간 방치 후 행크염 용액 1㎖ 를 가하면서 세포를 재부유시킨 다음 세포 부유액을 혈구 계산판(American 0ptica Buffalo, N.Y., U.S.A)위에 한 방울 떨어뜨리고 450배율로 검경 관찰하였다. 비장세포에 면양적혈구가 4개이상 부착된 경우를 로제트 형성세포로 정하여 106비장세포당 103로제트 형성 세포수를 산정하였다.After the blood was collected, the mice were killed with cervical distal bone, and the abdomen was completely applied with alcohol to remove the spleen aseptically. Then, the tissues around the spleen were carefully removed and washed with cold RPMI medium. After finely crushing the prepared spleen and remove the debris and washed twice with RPMI medium. Thereafter, erythrocytes were destroyed with sterile distilled water, washed twice with 10 times Hank's balanced salt solution (HBSS) and once again with RPMI medium, followed by RPMI medium with 10% fetal bovine serum. The spleen lymphocytes were resuspended. The splenocyte suspension was adjusted to a concentration of 1 × 10 7 cells / ml and the surface cell suspension, adjusted to a concentration of 3 × 10 8 cells / ml, by 0.5ml each, and centrifuged at 980 rpm for 5 minutes. After standing at 4 ° C. for 30 minutes, the cells were resuspended with 1 ml of Hank's salt solution, and then the cell suspension was dropped on a hemocytometer (American 0ptica Buffalo, NY, USA) and examined at 450 magnification. The number of 10 3 rosette-forming cells per 10 6 splenocytes was determined as a rosette forming cell in which 4 or more sheep cells were attached to splenocytes.

그 결과 대조군이 25.03 ±2.58인데 비하여, 가미보아탕 50 mg/kg 투여군이 49.64 ±5.72로 대조군에 비하여 2배 가까운 증가를 보였으며 P〈0.05의 유의성도 인정되었다(표 5).As a result, the control group was 25.03 ± 2.58, while the 50 mg / kg administration group was 49.64 ± 5.72, nearly double the increase compared to the control group, and the significance of P <0.05 was also recognized (Table 5).

[표 5] 가미보아탕 투여가 로제트 형성 세포수에 미치는 영향Table 5 Effect of Gamiboa-tang Administration on Rosette-forming Cell Number

a) : 평균 ± 표준편차a): mean ± standard deviation

* : 스튜던트 T테스트 결과 대조군에 비해 통계적으로 유의적인 증가를 보임*: Student T test showed statistically significant increase compared to control

( p〈0.05).(p <0.05).

○임파구 증식치 측정○ Lymphocyte proliferation level measurement

위의 방법으로 부유된 비장임파구를 1×106cells/㎖의 농도로 조정한 뒤, T임파구 유사분열 유도물질인 Concanavalin-A (Sigma, U.S.A)를 10㎕/㎖의 농도로 첨가하고, 96 웰(well) 배양용기에 웰(well)당 100㎕씩 분주한 후, 37℃ 5% 이산화탄소 배양기에서 72시간 배양하였다. [3H]-티미딘(New England Nuclear, Boston MA, U.S.A)을 첨가한 후 18시간 동안 추가 배양하였다. 그 후 자동 세포 수집기(SKATRON, Skatron instrument, Norways)로 유리섬유필터 상에 수거 한 후 이를 온실에서 건조시킨 뒤 방사능 측정 용기에 넣어 5㎖의 측정 칵테일 용액(5g PPO, 250mg P0P0P을 toluene 1ℓ에 녹임)으로 용해시킨 후 β선 동위원소 측정기(Beckman, LS 3801, U.S.A.)에서 DNA합성시 함입된 [3H]-티미딘양을 counter per minute(cpm)으로 측정하였다. 실험결과 대조군이 142.76 ±24.88 cpm 인데 비하여, 가미보아탕 50 mg/kg 투여군이 896.48 ±54.21 cpm으로 증가하였으며 P〈0.05의 유의성이 인정되었다(표 6).Adjust the suspended spleen lymphocytes to a concentration of 1 × 10 6 cells / ml by the above method, and then add Concanavalin-A (Sigma, USA), a T lymphocyte mitosis inducer, at a concentration of 10 μl / ml, and 96 100 μl per well was dispensed into a well culture vessel, and then cultured in a 37 ° C. 5% carbon dioxide incubator for 72 hours. [ 3 H] -thymidine (New England Nuclear, Boston MA, USA) was added followed by further incubation for 18 hours. Thereafter, the cells were collected on a glass fiber filter using an automatic cell collector (SKATRON, Skatron instrument, Norways), dried in a greenhouse, and placed in a radioactive measuring container and dissolved in a 5 ml measuring cocktail solution (5 g PPO, 250 mg P0P0P in 1 L of toluene). After dissolution, the amount of [ 3 H] -thymidine incorporated during DNA synthesis in a β-ray isotope detector (Beckman, LS 3801, USA) was measured by counter per minute (cpm). As a result, the control group was 142.76 ± 24.88 cpm, whereas the Kamigaatang 50 mg / kg administration group was increased to 896.48 ± 54.21 cpm and the significance of P <0.05 was recognized (Table 6).

[표 6] 가미보아탕이 임파구 증식에 미치는 영향[Table 6] Effect of Gamiboa-tang on Lymphocyte Proliferation

a) : 평균 ±표준편차a): mean ± standard deviation

* : 스튜던트 T테스트 결과 대조군에 비해 통계적으로 유의적인 증가를 보임*: Student T test showed statistically significant increase compared to control

( p〈0.05).(p <0.05).

○ 탄소제거율(carbon clearance)에 의한 거식세포 활성도에 대한 효과○ Effects on Macrophage Activity by Carbon Clearance

거식세포 활성도의 측정은 생쥐의 미정맥에 탄소 16㎎을 주사한 후 1분, 5분에 안와에서 25㎕씩 혈액을 마이크로피펫(micropipette)으로 채취하고 0.1% Na2CO32㎖에 용혈시켜 분광광도계(Spectrophotometer, U-2000, Hitachi, Japan)를 사용하여 파장 675nm에서 미소혈관내 탄소농도를 측정하였으며, 탐식지수 K는 아래의 공식에 의하여 산출하였다.Macrophage activity was measured by injecting 16 mg of carbon into the vein of the mouse and collecting 25 μl of blood from the orbit at 1 minute and 5 minutes with a micropipette, and then hemolyzed in 2 ml of 0.1% Na 2 CO 3. The spectrophotometer (Spectrophotometer, U-2000, Hitachi, Japan) was used to measure the carbon concentration in the microvascular at 675 nm wavelength. The index K was calculated by the following formula.

C1: 시간 T1에서의 시료 혈액중의 탄소 농도C 1 : carbon concentration in sample blood at time T 1

C2: 시간 T2에서의 시료 혈액중의 탄소 농도C 2 : carbon concentration in sample blood at time T 2

T1: 처음 채혈시간T 1 : initial blood collection time

T2: 마지막 채혈시간T 2 : last blood collection time

실험군과 대조군간의 거식세포활성도를 비교해보기 위하여 생쥐의 미정맥에탄소를 주사하여 탄소제거율을 측정하였던 바, 대조군의 phagocytic index K값이 0.00698 ±0.00040 인데 비하여, 가미보아탕 50mg/kg 투여군은 0.01452 ±0.00049로 증가하여 대조군에 비하여 P〈0.01의 유의성이 인정되었다(표 7).In order to compare the macrophage activity between the experimental group and the control group, the carbon removal rate was measured by injecting carbon into the vein of the mouse. Increased to 0.00049, the significance of P <0.01 compared to the control was recognized (Table 7).

[표 7] 가미보아탕이 거식세포 활성도에 미치는 영향[Table 7] Effect of Gamiboa-tang on Macrophage Activity

a) : 평균 ±표준편차a): mean ± standard deviation

* : 스튜던트 T테스트 결과 대조군에 비해 통계적으로 유의적인 증가를 보임*: Student T test showed statistically significant increase compared to control

( p〈0.01).(p <0.01).

[실시예 7]Example 7

〈가미보아탕과 아가리쿠스의 혼합한 보가리탕(BKR)에 있어서의 항암효과 상승작용〉〈Synthesis effect of anti-cancer effect in bogari-tang (BKR) mixed with kamiboa-tang and agaricus>

4주령 ICR 마우스에 2 x 105개의 Sarcoma-180 암세포를 복강주사하고 1일 1회씩 15일간 시료를 경구 투여 하였다. 암세포 주사후 30일 후에 살아 있는 마우스의 백분율을 관찰하였다. 실험결과 대조군은 0 %의 생존율을 보인데 반해, 가미보아탕 투여군은 10 %, 아가리쿠스 투여군은 20 %의 생존율을 보였다. 가미보아탕과아가리쿠스를 혼합한 보가리탕을 처리한 경우는 50 %의 생존율을 보여 강한 항암효과의 상승작용이 관찰되었다(표 8).Four-week-old ICR mice were intraperitoneally injected with 2 x 10 5 Sarcoma-180 cancer cells, and the samples were orally administered once a day for 15 days. Percentage of live mice was observed 30 days after cancer cell injection. As a result, the control group showed a survival rate of 0%, whereas the Gamiboa-tang group showed 10% survival rate and the agaricus group 20% survival rate. When treated with kamiboa-tang and agaricus-based bogari-tang, 50% survival rate was observed, indicating a strong anticancer effect (Table 8).

[표 8] 가미보아탕과 아가리쿠스를 혼합한 보가리탕(BKR)의 항암효과 상승작용[Table 8] Antitumor Effect of Bogari-tang (BKR) Mixed with Kamiboa-tang and Agaricus

상기에서 알 수 있는 바와 같이, 28 가지의 한방로 구성된 가미보아탕은 암세포에 대한 직접적인 성장억제 작용은 없었으나 생체면역기능을 활성화 시킴으로써 암 생존률 증가, 암크기 감소, 암전이 억제 등의 항암활성을 나타내었다. 기존의 암 치료법인 방사선 치료법과 화학 항암제 치료법이 골수, 면역계 손상의 부작용을 나타냄에 비교하여 볼 때 면역계를 활성화시킴으로써 암을 제거하는 가미보아탕은 부작용 없고 암환자의 삶의 질을 크게 향상시킬수 있는 암 치료제이다. 또한항암효과로 널리 알려져 있는 아가리쿠스 버섯과 혼합하여 투여하였을 경우, 가미보아탕은 아가리쿠스 버섯의 항암 효과를 크게 증가시켰음을 볼 때 가미보아탕은 기존의 항암 약제 또는 항암 식품과 혼합하여 투여함으로써 더욱 우수한 효과를 기대할 수 있다.As can be seen from the above, Gamiboa-tang, which consists of 28 herbal medicines, had no direct growth inhibitory effect on cancer cells, but activated bioimmune functions to increase cancer survival rate, decrease cancer size, and inhibit cancer metastasis. Indicated. Compared to conventional cancer treatments such as radiation therapy and chemotherapy, the side effects of bone marrow and immune system damage have been shown. It is a cancer drug. Also, when mixed with agaricus mushroom, which is widely known as an anticancer effect, gamiboa-tang increased the anti-cancer effect of agaricus mushroom. You can expect the effect.

Claims (2)

6-24중량부의 안중산 제제; 25-100중량부의 보화환 제제; 그리고 각각 1-6중량부의 해표소, 계내금, 오공, 건칠, 반지련, 지모 및 0.25-1중량부의 목향으로 이루어진 암치료용 한방 조성물6-24 parts by weight of the eye acid preparation; 25-100 parts by weight of a ring-shaped formulation; And herbal compositions for cancer treatment, each consisting of 1-6 parts by weight of shedding point, gynecological intake, five-hole, dried lacquer, jinryum, jimo and 0.25-1 parts by weight 제 1 항에 있어서, 35-150중량부의 아가리쿠스 버섯으로 더 구성되는 것을 특징으로 하는 암 치료용 한방 조성물The herbal composition for treating cancer according to claim 1, further comprising 35-150 parts by weight of agaricus mushroom.
KR1019990010867A 1999-03-29 1999-03-29 Chinese medicine for cancer treatment KR100316379B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019990010867A KR100316379B1 (en) 1999-03-29 1999-03-29 Chinese medicine for cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990010867A KR100316379B1 (en) 1999-03-29 1999-03-29 Chinese medicine for cancer treatment

Publications (2)

Publication Number Publication Date
KR20000061656A true KR20000061656A (en) 2000-10-25
KR100316379B1 KR100316379B1 (en) 2001-12-12

Family

ID=19578112

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990010867A KR100316379B1 (en) 1999-03-29 1999-03-29 Chinese medicine for cancer treatment

Country Status (1)

Country Link
KR (1) KR100316379B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100425978B1 (en) * 2001-09-13 2004-04-06 조정원 Compositions having Anti-cancer Activities
KR100516351B1 (en) * 2002-11-05 2005-09-26 학교법인 경희대학교 Pharmaceutical Compositions having Anti-cancer and antimetastatic Activities
KR100793019B1 (en) * 2005-11-25 2008-01-08 보령메디앙스 주식회사 Cosmetic composition containing an extract of Lespedeza bicolor Turcz., Glechoma hederacea var. longituba Nakai and Portulaca grandiflora Hooker for anti-oxidative and anti-inflammatory activity

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100394539B1 (en) * 2001-03-02 2003-08-14 지정아 Method for manufacturmg a drink mainly made from an Agaricus mushroom
CN104069295A (en) * 2014-06-04 2014-10-01 于新钟 Medicament with effects of removing tumors, resisting cancers and relieving pain

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100425978B1 (en) * 2001-09-13 2004-04-06 조정원 Compositions having Anti-cancer Activities
KR100516351B1 (en) * 2002-11-05 2005-09-26 학교법인 경희대학교 Pharmaceutical Compositions having Anti-cancer and antimetastatic Activities
KR100793019B1 (en) * 2005-11-25 2008-01-08 보령메디앙스 주식회사 Cosmetic composition containing an extract of Lespedeza bicolor Turcz., Glechoma hederacea var. longituba Nakai and Portulaca grandiflora Hooker for anti-oxidative and anti-inflammatory activity

Also Published As

Publication number Publication date
KR100316379B1 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
CA1299100C (en) Extracts of nerium species, methods of preparation and use therefor
JP2020172523A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
CN102697035A (en) Cordyceps anti-aging pellet
Li et al. An introductory note to ginseng
EP2040726A1 (en) Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases
US5759543A (en) Application of a cell culture of a fusarium fungus strain producer for medical uses
CN109432332A (en) A kind of Chinese medicine powder and preparation method thereof for treating gout and hyperuricemia
KR100316379B1 (en) Chinese medicine for cancer treatment
JP2012067023A (en) Composition for improving biofunction containing essence of cistanche deserticola y. c. ma
KR0160108B1 (en) Anticancer agent of raw ingredient extracted from the tree named gleditschia officinalis
CN109602759A (en) The purposes of kusamaki broad-leaved podocarpus seed and receptacle polysaccharide
CN110448625B (en) Traditional Chinese medicine composition for treating hypoxic kidney injury diseases, preparation method and application thereof
CN108567914A (en) It is a kind of that there is the Chinese medicine preparation and its preparation method and application for improving sleep effect
CN107519327A (en) A kind of Phellinus Chinese medicine composition and its extracting method and the application in antineoplastic is prepared
CN100589812C (en) Plant worms mycelium extracat fraction and composition for oral intake
KR100607907B1 (en) Pharmaceutical composition containing Phellinus linteus extract for preventing cancer metastasis to liver and excellent in immunomodulation
ES2311086T3 (en) SPORTS OF GANODERMA LUCIDUM FOR THE TREATMENT OF LUPUS ERITEMATOSOS SISTEMICO (SLE).
EP0246069A2 (en) Extracts of nerium species, methods of preparation, and use therefore
KR101985660B1 (en) Cosmetic composition for treating acne containing mixed herbal extracts fermented with Nuruk
CN104127545B (en) New application of murraya tetramera huang and extract thereof in preparation of medicines
CN104840747B (en) Chinese medicine composition with antithyroid cancer activity and its preparation method and application
Naman et al. Anti-Anaemic Potential of Methanolic Leaf Extract of Mucuna Pruriens on Phenylhydrazine (Phz) Induced Anaemic Albino Wistar Rats
CN116492369B (en) Traditional Chinese medicine polysaccharide composition with anti-inflammatory and hemostatic effects and application thereof
KR102590151B1 (en) Pharmaceutical composition for preventing or treating of pancreatic cancer comprising medicinal herb complex extract
US20060039999A1 (en) Pharmaceutical composition for inhibition of tumor growth or metastasis

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121105

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20131022

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20140925

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20150831

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20161102

Year of fee payment: 16

LAPS Lapse due to unpaid annual fee